Antileukoproteinase polyclonal, anti-human, mouse, rat

Protein Family: Chaperones and Folding Catalysts

Pathway and Disease: Folding, Sorting and Degradation

Description:
Antileukoproteinase (ALP) is an acid-stable proteinase inhibitor with strong affinities for trypsin, chymotrypsin, elastase, and cathepsin G. ALP prevents elastase-mediated damage to oral and possibly other mucosal tissues. The inflammation-mediated release of neutrophil elastase in the lungs of patients whose levels of active alpha-1-antiprotease are compromised by genetic background, cigarette smoking, air pollutants, or a combination of all three can result in severe lung damage and a decreased lifespan. The relatively small size of ALP, its lack of glycosylation and its stability make this protein a candidate for use as a therapeutic agent in diseases mediated by leukocyte elastase-antielastase imbalances.

Alternate Names: Antileukoproteinase, ALP, Secretory leukocyte protease inhibitor, HUSI-1, Seminal proteinase inhibitor, BLPI, Mucus proteinase inhibitor, MPI, WAP four-disulfide core domain protein 4, Protease inhibitor WAP4, SLPI, WAP4, WFDC4

Application Notes: E: 1:10,000-1:40,000; WB: 1:200-1:500

Accession No.: P03973

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human antileukoproteinase.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.